Geneva, March 20 -- International Clinical Trials Registry received information related to the study (NCT07443397) titled 'Anlotinib Plus Whole-Brain Radiotherapy for Brain Metastases in SCLC Patients' on Feb. 25.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Condition:
Whole-Brain Radiotherapy
Intervention:
Drug: Anlotinib
Recruitment Status: Recruiting
Phase: Phase 3
Date of First Enrollment: August 29, 2025
Target Sample Size: 134
Countries of Recruitment:
China
To know more, visit https://clinicaltrials.gov/study/NCT0744...